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Background: Our aim was to develop a new protocol for MGMT immunohistochemistry with good agreement
between observers and good correlation with molecular genetic tests of tumour methylation. We examined 40
primary brain tumours (30 glioblastomas and 10 oligodendroglial tumours) with our new technique, namely
double-labelling immunohistochemistry for MGMT and a "cocktail" of non-tumour antigens (CD34, CD45 and CD68).
We compared the results with single-labelling immunohistochemistry for MGMT and methylation-specific multiplex
ligation-dependent probe amplification (MS-MLPA, a recognised molecular genetic technique which we applied as
the gold-standard for the methylation status).
Results: Double-labelling immunohistochemistry for MGMT produced a visual separation of tumourous and
non-tumourous elements on the same histological slide, making it quick and easy to determine whether tumour
cell nuclei were MGMT-positive or MGMT-negative (and thereby infer the methylation status of the tumour). We
found good agreement between observers (kappa 0.76) and within observer (kappa 0.84). Furthermore,
double-labelling showed good specificity (80%), sensitivity (73.33%), positive predictive value (PPV, 83.33%) and
negative predictive value (NPV, 68.75%) compared to MS-MLPA. Double-labelling was quicker and easier to assess
than single-labelling and it outperformed quantitative computerised image analysis of MGMT single-labelling in
terms of sensitivity, specificity, PPV and NPV.
Conclusions: Double-labelling immunohistochemistry for MGMT and a cocktail of non-tumourous elements
provides a "one look" method for determining whether tumour cell nuclei are MGMT-positive or MGMT-negative.
This can be used to infer the methylation status of the tumour. There is good observer agreement and good
specificity, sensitivity, PPV and NPV compared to a molecular gold-standard.
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Clinical trials have shown that determination of the
methylation status of glioblastomas is an important pre-
dictor of outcome and response to treatment [1–4]. A
range of molecular genetic techniques are available for de-
termining methylation status in tumours [5]. However,
these are generally expensive and somewhat slow in
application. It would certainly be of great help if immuno-
staining were available to infer the methylation status of
the tumour. In fact, immunostaining for MGMT, on the
face of it, should provide an answer. Antibodies against
MGMT are readily available which stain tumour cell nu-
clei positive in unmethylated tumours and negative in
methylated tumours (this opposite relationship between
MGMT staining and methylation status is due to the fact
that methylation of the MGMT gene switches off produc-
tion of the MGMT protein) [6].
However, there is a major problem in interpretation of
MGMT immunostaining in brain tumours due to the fact
that normal non-tumourous elements within the tumour
(including endothelial cells, lymphocytes and macro-
phages) normally express MGMT [6–8]. This makes it
difficult to determine whether any MGMT positivity
within the tumour is due to tumour cells or non-tumour
cells. Not surprisingly, the literature therefore contains
much controversy about the value or otherwise of MGMT
immunostaining as a clinical biomarker in brain tumours
(please see Table 1).
For example, Preusser et al. [6] state that observer
variability and lack of association with patient survival
impedes the use of MGMT immunostaining in glioblast-
omas. On the other hand, Watanabe et al. [9] (on the
basis of eight years clinical experience of MGMT immu-
nostaining, using serial sections stained for non-tumour
markers such as CD45 and CD68 and a careful algorith-
mic approach) consider that MGMT immunohisto-
chemistry correlates with outcomes in patients with
glioblastomas.
Although the use of serial sections stained with non-
tumour markers for comparison with sections stained for
MGMT is undoubtedly helpful, it is not always easy to
compare cellular identities between serial sections. To
some extent it is possible to identify tumour cells in the
MGMT-stained section directly (for example, when
tumour cell nuclei are very large and bizarre). However,
reactive elements within tumours may themselves develop
a degree of nuclear enlargement and irregularity which
makes distinction from tumour cells impossible at times.
Double-labelling immunohistochemistry is an estab-
lished technique which is now available on some auto-
mated immunohistochemistry platforms such as the
Leica platform in use in our laboratory. This means that
double-labelling protocols can readily be incorporated
into the routine work of the laboratory, with much thesame turnaround time as standard immunohistochemis-
try and at little extra cost.
We have used such a platform to develop a novel
technique, namely double-labelling immunostaining of
MGMT and a "cocktail" of non-tumour antigens (CD34,
CD45 and CD68). Our aim was to produce a visual separ-
ation of tumour cells and non-tumour cell elements on
the same histological slide and thereby greatly simplify the
assessment of MGMT immunostaining in tumour cell
nuclei.
Results
A comparison of the results for double-labelling versus
single-labelling and MLPA (the gold standard) is shown
in Table 2. Some representative examples of single-
labelling and double-labelling are shown in Figure 1.
Agreement in assessment of the double-labelling
There was good inter-observer and intra-observer agree-
ment in the assessment of the double-labelling. For the
three independent "blind" observers (EB, LB and KE) all
appraisers’ assessments agreed with each other for 31/40
(77.50%) of the cases. The Fleiss’ kappa statistic was 0.76
and Kendall’s coefficient of concordance for ordinal
scores was 0.93 indicating a good level of agreement.
The intra-observer agreement was 36/40 (90%) of cases
matched with a kappa of 0.84 and a Kendall of 0.97.
Sensitivity, specificity, positive predictive value and
negative predictive value of double-labelling
The results of the neuropathologist (LB) were compared
with the gold standard, MLPA. For this, cases assessed
as largely MGMT-negative were considered methylated
(i.e. test result positive) and cases assessed as largely
MGMT-positive were considered unmethylated (i.e. test
result negative). For MLPA we use the cut-off used by
Jeuken et al. [10]. According to this, all cases with an
MLPA ratio greater than 0.25 are at least mildly methyl-
ated (i.e. true positives) and cases with an MLPA ratio of
between 0 and 0.25 are unmethylated (i.e. true negatives).
Of the 40 cases, there were 11 negative matches, 20
positive matches, 4 false-positives and 5 false-negatives.
The test results showed significant association (chi-square,
p = 0.001) between the double-labelling and MLPA
results. Sensitivity was 80%, specificity 73.33%, positive
predictive value (PPV) 83.33% and negative predictive
value (NPV) 68.75%. For the 30 glioblastomas apart, sensi-
tivity was 66.7%, specificity 73.33%, PPV 71.43% and NPV
68.75%. All 10 of the oligodendroglial tumours were cor-
rectly called. These values indicate a good all-round per-
formance by the double-labelling.
The other assessors’ results were also compared with
MLPA. The results for specificity, sensitivity, PPV and
NPV were 88%, 46.67%, 73.33% and 70% for KE and 88%,
Table 1 Previous studies













Nakasu et al. 2004 [7] 69 high-grade gliomas
(grades III and IV)
10% - Yes No - -
Brell et al. 2005 [11] 93 anaplastic gliomas: 75 AAs and 18
with oligodendroglial component
5% No Yes Yes MS-PCR No
Chinot et al. 2007 [21] 28 GBMs 35% Yes Yes No - -
Capper et al. 2008 [22] 75 primary GBMs 15% Yes – median survival No - -
Preusser et al. 2008 [6] 164 GBMs 10% - No Yes MS-PCR Poor agreement
Rodriguez et al. 2008 [23] 50 GBMs 10% No No Yes MS-PCR No




Quillien et al. 2012 [5] 100 GBMs 23% Yes Yes No - -
The table shows previous studies where MGMT IHC has been performed. The cut-off value was the percentage of MGMT-positive tumour cell nuclei (assessed by eye). The correlation of IHC with progression-free
survival (PFS) and overall survival (OS) and comparison with a molecular gold standard (where applied) are also shown.























case ID type LI SL MLPA MLPA 0-3 MLPA >0.25 DL
1 oligo 7.567 1 0.6275 2 1 1
2 oligo 13.700 1 0.675 2 1 1
3 oligo 12.600 1 0.8075 3 1 1
4 oligo 24.667 1 0.4725 1 1 1
5 oligo 17.100 1 0.8525 3 1 1
6 oligo 13.600 1 0.8025 3 1 1
7 oligo 19.567 1 0.6425 2 1 1
8 oligo 14.267 1 0.6925 2 1 1
9 oligo 8.800 1 0.6525 2 1 1
10 oligo 26.133 1 0.5925 2 1 *1
11 gbm 56.367 0 0.1125 0 0 0
12 gbm 19.167 1 0.8475 3 1 1
13 gbm 84.400 0 0.09 0 0 0
14 gbm 17.967 1 0.2625 1 1 *1
15 gbm 57.700 0 0.255 1 1 0
16 gbm 89.900 0 0.4075 1 1 0
17 gbm 72.267 0 0.2075 0 0 0
18 gbm 19.533 1 0.3525 1 1 *1
19 gbm 54.133 0 0.42 1 1 *1
20 gbm 53.900 0 0.1375 0 0 0
21 gbm 21.967 1 0.485 1 1 1
22 gbm 54.167 0 0.5475 2 1 1
23 gbm 33.000 1 0.085 0 0 0
24 gbm 76.300 0 0.2725 1 1 0
25 gbm 96.733 0 0.24 0 0 0
26 gbm 49.567 1 0.4275 1 1 1
27 gbm 43.967 1 0.1375 0 0 *1
28 gbm 40.533 1 0.1025 0 0 0
29 gbm 7.233 1 0.1275 0 0 1
30 gbm 39.067 1 0.5125 2 1 1
31 gbm 25.833 1 0.2075 0 0 *1
32 gbm 33.900 1 0.13 0 0 *1
33 gbm 28.000 1 0.365 1 1 0
34 gbm 45.000 1 0.275 1 1 1
35 gbm 84.100 0 0.205 0 0 0
36 gbm 85.100 0 0.2975 1 1 0
37 gbm 64.933 0 0.11 0 0 0
38 gbm 53.400 0 0.17 0 0 0
39 gbm 6.800 1 0.825 3 1 1
40 gbm 22.500 1 0.2425 0 0 0
Case ID (identification) is the case number we assigned in this study. Tumour types were oligodendroglial tumours (oligo) and glioblastomas (gbm). The
oligodendroglial tumours were oligodendroglioma WHO grade II (cases 4, 5 and 6), anaplastic oligodendroglioma WHO grade III (cases 1, 2, 3, 7 and 9),
oligoastrocytoma WHO grade II (case 10) and anaplastic oligoastrocytoma WHO grade III (case 8). The glioblastomas were all glioblastoma WHO grade IV except
cases 13 and 18 which were glioblastoma with oligodendroglioma component WHO grade IV. LI is the nuclear labelling index for single-labelled MGMT as
determined by computerised image analysis. SL is the binarised score for the single-labelling (0 = LI > 50%, 1 = LI from 0 to 50%). MLPA is the MLPA ratio (please
see text). MLPA 0–3 is the score for MLPA according to cut-offs for the MLPA ratio provided by Jeuken et al. 2007 [10] (0 = unmethylated, 1 = mildly methylated,
2 = moderately methylated and 3 = extensively methylated). MLPA > 0.25 is the binarised methylation score for MLPA (0 = unmethylated, 1 =methylated). DL is
the binarised score for double labelling (0 = mainly MGMT-positive in tumour cells, 1 = mainly MGMT-negative in tumour cells). The asterisked cases were initially
assigned a score of 1 in the tripartite system (please see text for explanation).
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Figure 1 Photomicrographs comparing single-labelling and
double-labelling for MGMT. This figure shows the advantage of
double-immunolabelling over single-immunolabelling in the
interpretation of MGMT immunostaining. Four glioblastomas are
shown, one per row, with the single-labelling for MGMT on the left
and double-labelling for MGMT and "cocktail" (combined CD34,
CD45 and CD68) on the right. All images were photographed at an
objective lens magnification of 80x (scale bar = 50 microns). For all
images, nuclear immunostaining for MGMT is seen as brown due to
the DAB-peroxidase product. For images on the right, cytoplasmic
staining for CD34, CD45 and CD68 is seen as red due to the Fast
Red-Alkaline Phosphatase product used in the double-labelling
system. The counterstain is haematoxylin (nuclei unstained for
MGMT appear blue). The case in row 1 (case 25 in Table 2) was
unmethylated by MLPA. Double-labelling (B) is more informative
than single-labelling (A) because it highlights the cytoplasm of the
non-tumourous elements (endothelial cells, lymphocytes and
macrophages) as red. The remaining cells can therefore be positively
identified as tumour cells and the presence of undoubted nuclear
immunostaining for MGMT in these tumour cells correctly indicates
an unmethylated status. The case in row 2 (C and D; case 39 in
Table 2) was extensively methylated by MLPA. The case was easily
assessed as MGMT-negative (methylated) on double-labelling (D).
The case in row 3 (E and F; case 18 in Table 2) illustrates the issue of
"equivocal" staining as seen a number of cases (asterisked in
Table 2). Please see Results for further commentary on this
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LB’s apart from sensitivity which scored less well for these
assessors. This may reflect the particular approach of the
assessors; the neuropathologist appears to have been more
willing to ignore low levels of MGMT staining than the
two laboratory scientists. In this paper we have carried
forward the neuropathologist’s scores on the basis that the
pathologist carries out the everyday reporting in practice.
False-negatives and false-positives
Of the 5 false-negatives it is interesting to note that all
were only mildly methylated on MLPA. The slides were
reviewed and all 5 cases were confirmed as showing un-
doubted MGMT-positivity suggestive of an unmethylated
status. It is therefore of interest that although these cases
were false negatives, the result of MLPA was only mild
methylation – the closest category to unmethylated. Fur-
ther clinicopathological correlation may help develop a
better understanding of the significance of the "mildly"
methylated category on MLPA.
The slides of the 4 false-positives were also reviewed.
One case was undoubtedly MGMT-negative suggestive of
phenomenon. The case in row 4 (case 22 in Table 2) illustrates a
situation where single-labelling (G) shows a high labelling index for
MGMT due to a high content of non-tumourous cells (endothelial
cells, lymphocytes and macrophages). Double-labelling (H) provides
an easy "one-look" diagnosis of MGMT-negative (methylated).a methylated status but MLPA was unmethylated. The
other 3 cases showed equivocal MGMT-immunostaining
and we had chosen by convention to call these MGMT-
negative (please see below).
Equivocal MGMT-immunostaining
Table 2 shows 7/40 cases (asterisked) with equivocal
(focal or faint) MGMT-immunostaining of tumour cell
nuclei on double-labelling. For illustrations of equivocal
staining please see Figure 1 (E and F). These cases were
difficult to classify as MGMT-negative (methylated) or
MGMT-positive (unmethylated). We therefore decided
on a convention by which such cases were interpreted as
MGMT-negative (suggestive of a methylated status). Of
the 7 such cases, 4 cases (3 glioblastomas and 1 oligo-
dendroglial tumour) turned out to be correctly thus-
called (i.e. they were methylated by MLPA). Three cases
(all glioblastomas) were incorrectly called (i.e. they were
unmethylated).
Since there is no clear indication at present from these
figures as to how the equivocal cases should be assessed
(roughly equal numbers were methylated and unme-
thylated) we suggest - until more data is available -
treating these cases as MGMT-negative (suggestive of a
methylated status) as we have here. It may be worth not-
ing in the pathology report that such cases - in particular -
Figure 2 Chart of MGMT single-labelling, MGMT double-
labelling and MLPA status. The chart shows the labelling index for
MGMT from the single-labelled slides on the Y-axis for the 40 cases
plotted against the results of double-labelling and MLPA status. The
4 cases that were false-positive by double-labelling are seen in the
second column from the left. All of these cases have a labelling
index of less than 50% by single-labelling suggestive of a
methylated status. The results of double-labelling and single-
labelling are therefore concordant and combined analysis would not
have avoided calling these cases (falsely) positive. The 5 cases that
were false-negative by double-labelling are seen in the third column
from the left. Of these, 4 have a labelling index of greater than 50%
by single-labelling suggestive of an unmethylated status. The results
of double-labelling and single-labelling of these 4 cases are
therefore concordant and combined analysis would not have
avoided calling these (falsely) negative. Only one of the 5 false-
negative cases has a labelling index of less than 50% by single-
labelling suggestive of a methylated status. In this case the labelling
index might have been helpful in avoiding calling this (falsely)
negative on double-labelling. Overall however the extra effort
involved in measuring the labelling index by automated quantitative
image analysis on the single-labelled slides may not be worthwhile,
particularly in labs not set up for image analysis.
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through. This approach would seem most consistent with
the default clinical position whereby patients with glio-
blastomas in which the methylation status is unknown are
managed as if the tumour were methylated. We are gath-
ering further data on the issue of equivocal staining which,
as indicated, accounts for about a fifth of our assessments.
Comparison with single-labelling
As mentioned, Figure 1 shows how quantitative assess-
ment of double-labelling is quick and easy compared to
single-labelling. We wondered how the automated as-
sessment of the labelling index for MGMT on single-
labelling performed against the qualitative assessment
on double-labelling. For this we set a convenient cut-off
of 50% for the labelling index (close to the actual median
of 47.28 for the 40 cases in our series). Cases with a la-
belling index of up to 50% were considered methylated
(i.e. a positive test result) and cases with a labelling
index greater than 50% were considered unmethylated
(i.e. a negative test result) and this was compared with
MLPA using the 0.25 cut-off of Jeuken et al. [10] as pre-
viously detailed. Please note that our choice of a median
cut-off for the single-labelled MGMT labelling index
may at first sight appear to be a departure from previous
studies (e.g. Preusser et al. [6]). Generally these other
studies have used assessment "by eye” and mentally
subtracted tumour-only elements whereas our data is
truly quantitative and applied to both tumourous and
non-tumourous elements since the machine cannot sep-
arate the two. We feel that the median cut-off is appro-
priate in our context.
For all cases (n = 40) for the single-labelling MGMT la-
belling index versus MLPA sensitivity was 76%, specificity
55.33%, PPV 73.08% and NPV 57.14%. For the glioblast-
omas (n = 30) sensitivity was 60%, specificity 53.33%, PPV
56.25% and NPV 57.14%. Compared to double-labelling
these results for quantitative single-labelling are not as
good and there are also other disadvantages compared to
double-labelling (please see Discussion).
We then wondered whether the single-labelling and
double-labelling could be combined in some way to give
a better result and the analysis is shown in Figure 2.
Discussion
We have developed a novel protocol for the analysis of
MGMT-immunostaining using double-labelling. The aim
of our approach is to simplify the assessment of MGMT-
immunostaining by creating a visual separation of the
tumourous and non-tumourous elements. We did this by
using the usual brown chromogen (DAB-peroxidase) for
nuclear MGMT staining and a red chromogen (Fast Red-
Alkaline Phosphatase) for a “cocktail" of non-tumourous
cytoplasmic elements. The cocktail is composed of CD34(for endothelium), CD45 (for lymphocytes) and CD68 (for
macrophages). The end result was a histology slide in
which we could easily distinguish between tumourous and
non-tumourous components and thereby quickly come to
a conclusion as to whether the tumour cell nuclei were
MGMT-positive or MGMT-negative (and thence to a
conclusion as to their likely methylation status).
We found good agreement between observers (kappa
0.76) and within observer (kappa 0.84). Furthermore,
double-labelling showed good specificity (80%), sensitiv-
ity (73.33%), positive predictive value (83.33%) and
negative predictive value (68.75%) compared to MLPA
(the gold-standard).
Compared to qualitative assessment of single-labelling
MGMT-immunostaining, we found double-labelling to
be much quicker and easier to assess (Figure 1). Further-
more, double-labelling outperformed even quantitative
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in terms of sensitivity, specificity, PPV and NPV. Further-
more, we did not find that much benefit would accrue
from combining the results of double-labelling with
quantitative single-labelling. Since quantitation is some-
what time-consuming we would therefore not necessarily
recommend using both double-labelling with quantita-
tive single-labelling on a routine basis: we consider
double-labelling alone to be sufficient for everyday
purposes.
We are aware that the double-labelling as with any test
is not perfect and that certain cautions are required in
interpretation. The cocktail of three reagents (CD34,
CD45 and CD68) should stain a good proportion of
non-tumourous elements but not necessarily all. For ex-
ample, there may also be non-neoplastic astrocytes and
oligodendrocytes which are not identified by the cock-
tail. For this reason we would recommend that interpret-
ation of the double-labelling be focussed on areas of
tumour proper and caution exercised in areas where
tumour is infiltrating largely normal tissues. We are also
aware that CD34 occasionally stains glioblastoma
tumour cells and in such situations tumour cells will be
stained red by the red chromagen and will thus be ex-
cluded from analysis. However, we feel the CD34 stain-
ing by glioblastomas cells is usually just focal so that it
should be possible in most cases to find interpretable
areas in the slide.
In our own current practice, we carry out double-
labelling for MGMT and "cocktail" (CD34, CD45 and
CD68) to come to an initial conclusion as to the likely
methylation status of the tumour. Our report contains a
caveat that this result may be overturned by MLPA.
Nevertheless, because of the quicker turnaround time of
immunohistochemistry compared to molecular genetic
testing, the clinicians find this helpful with their initial
management pending the definitive result from MLPA.
At present, all cases are followed up with MLPA for de-
finitive diagnosis of methylation status. It may be pos-
sible in time, when more information has been gathered
about double-labelling, to phase out some of the MLPA
testing.
In future studies we would like to compare the results
of double-labelling for MGMT and a “cocktail” of non-
tumourous elements to clinical outcomes. Quantitation of
MGMT expression in tumour cells in double-labelled im-
ages will require special thresholding protocols but should
provide useful comparison with the methylation ratios
obtained from MLPA. Although MLPA is a relatively new
technique for assessment of methylation status, in this re-
gard it has the advantage of providing a quantitative result.
The double-labelling-cocktail method may also be useful
in the study of heterogeneity of MGMT expression in
brain tumours. A number of recent studies [11–18] haveraised the question of whether or not a strict correlation
should really be expected between MGMT staining and
methylation status. For example, Kreth and colleagues
[12] found that patients with discordant results for
MGMT expression (determined by mRNA expression)
and methylation status did worse than concordant coun-
terparts. A molecular basis for MGMT expression inde-
pendent of methylation may apply in some situations [13].
Our double-labelling technique offers a possible new ap-
proach to investigate such questions.
Conclusions
We have developed a novel method for double-labelling
for MGMT, which is quick and easy to apply and might
readily be subsumed into routine reporting for glioblast-
omas (and other tumours). There is good inter-observer
and intra-observer agreement and, compared to a mo-
lecular genetic gold-standard, the method yields good
sensitivity, specificity, positive predictive value and nega-
tive predictive value as a predictor of methylation status.
Methods
The study was carried out in compliance with local re-
search ethics committee (LREC) guidelines as a service
development.
This was a retrospective study. Forty formalin-fixed
paraffin-embedded (FFPE) samples were obtained from
patients diagnosed with gliomas (10 oligodendroglial tu-
mours and 30 glioblastomas) from the archives of the
Cellular Pathology department at St George’s Hospital,
Tooting. The oligodendroglial tumours were from 2005
to 2010 and the glioblastomas were all from 2011. A
haematoxylin and eosin (H&E) stained section from each
sample was reviewed to ensure the specimen comprised
sufficient tumour for diagnosis and further testing.
Immunohistochemistry
Immunohistochemistry (IHC) staining was carried out
on 4 μm sections heated for 30 min at 60°C using Bond
III fully automated staining system with their Bond Poly-
mer Refine detection system and associated reagents
supplied by Leica Microsystems, Newcastle-Upon-Tyne,
UK.
Antigen retrieval and dilution was carried out according
to antibody: CD34 clone QBEND10 (Novocastra, Leica
Microsystems, UK) 1:100, CD45 clone 2B11&PD7/26
(DakoCytomation, Ely, UK) 1:500, MGMT clone 3.1
(Millipore, Thermo Fisher, UK) 1:100 with Epitope
Retrieval Solution 1 (pH6) at 100°C for 30 min, CD68
clone 514H12 (Novocastra, Leica Microsystems, UK)
1:100 with Epitope Retrieval Solution 2 (pH9) at 100°C for
20 min. All primary antibodies were applied to the section
for 15 min except MGMT that was applied for 30 min.
The MGMT antibody was optimized using tonsil as a
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internal positive control.
Double-labelling utilized a sequential IHC staining
method, incorporating a “cocktail” of CD34, CD45 and
CD68 as the first antibody visualized with the Bond
Polymer Red Refine detection system (supplied by Leica
Microsystems, Newcastle-upon-Tyne, UK) and MGMT
clone 3.1 as the second antibody.
Methylation-specific multiplex ligand-dependent probe
amplification (MS-MLPA)
Ten x 10 μm sections were used for DNA extraction
and subsequent MS-MLPA testing. The area of tumour
was manually micro-dissected to enrich the sample.
DNA extraction was performed using an in-house
method using heat for de-waxing and Chelex-100
and sodium acetate for DNA purification. The probe
mix was prepared by MRC Holland (Amsterdam,
The Netherlands) and the procedure was carried out
according to the guidelines supplied. MS-MLPA was
performed on the Beckman Coulter CEQ 8000. DNA
yields were quantified using a NanoDrop (Thermo-Sci-
entific, USA).
A methylation ratio was produced by using an average
methylation from 4 analysed probes. In fact 6 probes are
provided in the kit but the manufacturers have recently
recommended that only 4 are used because 2 of the
probes are not particularly informative. A result of either
methylated or unmethylated was obtained for the MS-
MLPA test. A ratio of less than or equal to 0.25 was used
as a cut-off for unmethylated cases in accordance with
Jeuken et al. [10]. It was also possible, according to
Jeuken et al. [10] to subcategorise the results as follows:
0 to 0.25 unmethylated, 0.26 to 0.50 mildly methylated,
0.51 to 0.75 moderately methylated and 0.76 to 1.00 ex-
tensively methylated. The analysis was performed using
the software program Coffalyser v7 (MRC Holland,
Netherlands).
Photography
The slides were viewed on a Nikon Eclipse 80i microscope
with a Nikon DS Ri1 12 megapixel camera attached. Im-
ages were captured with NIS-Elements BR 3.2 software on
a Dell precision T7500 PC. All of the images were cap-
tured under standard conditions of illumination. Tiff
images (1280 ×1024 pixels) were taken at an objective lens
magnification of 40×. At the outset of the session, part of
the slide with no tissue (blankfield) was viewed in the
microscope and a white balance carried out. The level of
illumination was monitored as being between 204 and 206
for the blankfield (between photographs the illumination
level was checked as being within the same range). Photo-
graphs were taken with a fixed exposure time and after
using the inbuilt focusing device.Validation and scoring
Quantitation of the labelling index for single-labelled
MGMT (number of stained nuclei divided by total number
of nuclei expressed as percentage) was carried out in the
software program imageJ version 1.46e from the National
Institute of Health (Rasband, W.S., http://rsbweb.nih.
gov/ij/). Three photomicrographs were taken by the
neuropathologist (LB) as representative of the tumour,
avoiding non-informative areas such as cortex and necrosis
and without knowledge of the methylation status. We use
the ImmunoRatio plug-in, which has been validated for the
assessment of the labelling index of nuclear markers in
breast cancer [19]. In our material we found good correl-
ation of the labelling index for MGMT single-labelling
obtained using ImageJ and ImmunoRatio compared to a
direct cell count (Pearson correlation coefficient r = 0 .90)
and a semiquantitative manual assessment by group of
observers (r = 0.80) in 11 oligodendroglial tumours [20].
Please note that one of these cases was omitted from our
final study due to insufficient tissue.
Scoring of the double-labelling was carried out from
photomicrographs. Slides were photographed “blind”
(i.e. without knowledge of the methylation status) by
the neuropathologist (LB) and the resulting 120 images
(three representative images from each of 40 cases)
were evaluated by LB and by two laboratory scientists
EB and KE. The scheme followed was that images with
mainly negative staining in tumour cell nuclei scored 0,
images with equivocal staining scored 1 and images
with mainly positive staining scored 2. The final score
for each observer was the modal average of their scores
for the three images. One observer (LB) carried out a
second set of scores after 72 hours. Inter-observer and
intra-observer kappa statistics were calculated using the
attribute agreement analysis function in the statistical
program Minitab 16. Photomicrographs were used to
standardise the comparison bearing in mind the differ-
ent skill-sets of the assessors (please note however that
LB works directly from the double-labelled glass slides
in everyday diagnosis).
Specificity, sensitivity, positive predictive value and
negative predictive value were calculated according to
standard formulae in comparison with the gold-standard
MLPA after cross-tabulating the results in Minitab 16.
For this, the tripartite double-labelling scores were
converted to a binary scoring system (0 and 1). Original
scores of 0 and 1 were mapped to 1 in the new system and
original scores of 2 were mapped to 0. This "reverse" scor-
ing was adopted in order to correspond to the scoring of
the MLPA (i.e. unmethylated = 0, methylated = 1). After
due consideration, we adopted a convention by which
MGMT-equivocal immunostaining was interpreted as
MGMT-negative (i.e. presumptive of a methylated status;
please see Results).
Burke et al. Acta Neuropathologica Communications 2013, 1:22 Page 9 of 10
http://www.actaneurocomms.org/content/1/1/22We wondered whether the "cocktail" (CD34, CD45 and
CD68) used in the double-labelling gave a comparable re-
sult to the component antigens used singly. Using a
thresholding method in image J we measured the area
fraction of staining in 10 oligodendroglial tumours for the
cocktail and for CD34, CD45 and CD68 stained singly.
There was good correlation between the area fraction for
the cocktail (range 3 to 8%) and the sum of the area frac-
tions for CD34, CD45 and CD68 stained singly (range 3 to
9%; Spearman's rho = 0 .76). The area fraction of the cock-
tail was somewhat lower than the combined area fractions
of the single labels consistent with a degree of overlap
in antigenicity of target cells (e.g. CD68-positive macro-
phages may also stain with CD45).
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